@prefix this: <http://bio2rdf.org/drugbank:DB05481_nanopub.RANj_fjs6xxfCkahmuIp-RjO28shSY_HQoSMBpsEi1lsE> .
@prefix sub: <http://bio2rdf.org/drugbank:DB05481_nanopub.RANj_fjs6xxfCkahmuIp-RjO28shSY_HQoSMBpsEi1lsE#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix v: <http://bio2rdf.org/bio2rdf_vocabulary:> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:publicationInfo ;
    a np:Nanopublication .
}
sub:assertion {
   d:DB05481 v:identifier "DB05481" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05481" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05481> ;
    dv:drugbank-id "DB05481" ;
    dv:x-cas <http://bio2rdf.org/cas:> ;
    dct:description "Alpha 1-antitrypsin is a glycoprotein primarily produced by hepatocytes, and to a lesser extent, immune system cells. Recombinant alpha 1-antitrypsin (rAAT) is produced from yeast, which unlike commercially available forms of plasma-derived AAT, eliminates the risk associated with blood-borne infectious agents and allows for a increased manufacturing.  rAAT belongs to a family of structurally-related proteins classified as serine protease inhibitors or SERPINS, which are known to inhibit several proteases including trypsin, cathepsin G, thrombin, tissue kallikrein, as well as neutrophil elastase. The proteinase/antiproteinase balance is believed to be important for maintaining healthy skin. The rAAT topical gel (Dermolastin™) is indicated for patients with atopic dermatitis and psoriasis. The company has indicated that other formulations for gastroenterological and urological indications will also be developed."@en ;
    dct:identifier "drugbank:DB05481" ;
    dct:title "Recombinant alpha 1-antitrypsin"@en ;
    a dv:Drug ;
    rdfs:label "Recombinant alpha 1-antitrypsin [drugbank:DB05481]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05481> .
}
sub:provenance {
   sub:assertion prov:wasDerivedFrom <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  dr:bio2rdf.dataset.drugbank.R3 dcat:distribution <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime ;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> .
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime ;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> .
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> prov:wasAttributedTo <http://drugbank.ca> .
}
sub:publicationInfo {
   sub:signature.MCwCFHd1lag72Xx- npx:hasPublicKey "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" ;
    npx:hasSignature "MCwCFHd1lag72Xx+J6NuxgYD4Z6S28mWAhQcT5gtQmdoiDF4aiZrhhd35izkLA==" ;
    npx:signedBy instance: .
  this: dct:created "2018-03-30T11:10:33.837+02:00"^^xsd:dateTime ;
    dct:license <https://creativecommons.org/licenses/by-nc/4.0/> ;
    npx:hasSignatureElement sub:signature.MCwCFHd1lag72Xx- ;
    prov:wasGeneratedBy process: .
  instance: prov:specializationOf codebase: ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475" ;
    prov:used version: ;
    prov:wasAssociatedWith instance: ;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  version: dct:isVersionOf codebase: ;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349" ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}